S. 387IntroducedPUBLIC LANDS AND NATURAL RESOURCES
Grand Canyon Protection Act
Arizona · Congressional oversight · Geography and mapping
Sponsor
Sen. Sinema, Kyrsten [D-AZ]
D · AZ
Key facts
Introduced: Feb 23, 2021
Chamber: Senate
Cosponsors: 1
Congress: 117th
Latest action · Jul 21, 2022
Committee on Energy and Natural Resources. Failed to report favorably.
Summary
Grand Canyon Protection Act
This bill withdraws 1,006,545 acres of federal lands in Arizona, including any land or interest in land acquired by the United States after enactment of this bill, from
- entry, appropriation, and disposal under the public land laws;
- location, entry, and patent under the mining laws; and
- operation of the mineral leasing and geothermal leasing laws and mineral materials laws.
The Government Accountability Office shall conduct a study of uranium stockpiles in the United States that are available to meet future national security requirements.
Summary by Congressional Research Service.
Timeline
- Jul 21, 2022Committee on Energy and Natural Resources. Failed to report favorably.
- Jun 7, 2022Committee on Energy and Natural Resources Subcommittee on Public Lands, Forests, and Mining. Hearings held. With printed Hearing: S.Hrg. 117-301.
- Feb 23, 2021Read twice and referred to the Committee on Energy and Natural Resources.
- Feb 23, 2021Introduced in Senate
Cosponsors
In the News
- House Unanimously Passes 9/11 Coin Bill to Fund Memorial Museum - Legis1
- King Charles and Queen Camilla Go Glam for State Dinner at the White House Hosted by Trumps - People.com
- NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387 - ICYMI - Proactive financial news
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - Quantisnow
- Good plasmons in a bad metal - Science | AAAS
- Congress is cracking down on private jet tracking — including Taylor Swift's - qz.com
- Navarro Is Sentenced to 4 Months in Prison for Stonewalling Congress (Published 2024) - The New York Times
- The Supreme Court’s Legitimacy Dilemma - Harvard Law Review
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer - The New England Journal of Medicine
- Nanoviricides (NNVC) Stock News & Updates - Stock Titan
View official record on Congress.gov →
Make your voice heard
Contact your representatives about this bill in under 2 minutes.
📬 Contact Your Reps →